MarketCap
Facebook
X
Telegram
argenx SE Net Income | ARGX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income argenx SE
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.29 B | 833 M | -295 M | -710 M | -408 M | -529 M | -163 M | -66.6 M | -28.1 M | -21.4 M | -15.3 M | -10.3 M | -6.13 M | -9.7 M | -3.46 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 B | -710 M | -9.38 M |
Quarterly Net Income argenx SE
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.29 B | 415 M | 833 M | -32.5 M | -295 M | -123 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 B | -295 M | 348 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Outlook Therapeutics
OTLK
|
-62.4 M | $ 0.6 | 0.42 % | $ 20.9 M |  USA |
 |
Ovid Therapeutics
OVID
|
-17.4 M | $ 2.34 | 0.21 % | $ 305 M | USA |
 |
Passage Bio
PASG
|
-7.56 M | $ 4.09 | 0.73 % | $ 13.1 M | USA |
 |
Puma Biotechnology
PBYI
|
31.1 M | $ 9.67 | 1.68 % | $ 484 M | USA |
 |
Processa Pharmaceuticals
PCSA
|
-13.6 M | $ 1.49 | 0.62 % | $ 1.95 M | USA |
 |
Vaxcyte
PCVX
|
-767 K | $ 73.82 | 30.7 % | $ 10 B | USA |
 |
PDS Biotechnology Corporation
PDSB
|
-7.56 M | $ 1.2 | 60.32 % | $ 55.7 M | USA |
 |
Pfizer
PFE
|
7.77 B | $ 27.41 | 0.02 % | $ 156 B | USA |
 |
Precigen
PGEN
|
-251 M | $ 7.74 | 4.02 % | $ 2.42 B | USA |
 |
Pharming Group N.V.
PHAR
|
33 M | $ 9.8 | 0.51 % | $ 6.75 B |  Niderland |
 |
Phathom Pharmaceuticals
PHAT
|
-221 K | $ 6.7 | 1.77 % | $ 489 M | USA |
 |
Phio Pharmaceuticals Corp.
PHIO
|
-8.7 M | $ 0.99 | 0.6 % | $ 5.92 M | USA |
 |
Pliant Therapeutics
PLRX
|
149 M | $ 1.03 | 0.48 % | $ 63.2 M | USA |
 |
Protalix BioTherapeutics
PLX
|
-6.6 M | $ 2.71 | 0.37 % | $ 213 M |  Israel |
 |
PMV Pharmaceuticals
PMVP
|
-77.7 M | $ 1.78 | 2.29 % | $ 93.5 M | USA |
 |
Praxis Precision Medicines
PRAX
|
-303 M | $ 283.56 | 3.0 % | $ 6.38 B | USA |
 |
PainReform Ltd.
PRFX
|
-5.02 M | $ 0.88 | 0.04 % | $ 570 K | Israel |
 |
Prelude Therapeutics Incorporated
PRLD
|
-99.5 M | $ 3.77 | 2.72 % | $ 290 M | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
-42.2 M | $ 1.67 | 2.14 % | $ 176 M | Niderland |
 |
Prothena Corporation plc
PRTA
|
-244 M | $ 8.27 | 0.35 % | $ 445 M | USA |
 |
PTC Therapeutics
PTCT
|
683 M | $ 63.65 | 0.3 % | $ 5.06 B | USA |
 |
Protagonist Therapeutics
PTGX
|
-130 M | $ 140.63 | 0.41 % | $ 8.94 B | USA |
 |
Pulmatrix
PULM
|
-1.17 M | $ 1.48 | 0.64 % | $ 5.41 B | USA |
 |
PolyPid Ltd.
PYPD
|
-34.2 M | $ 5.2 | 0.19 % | $ 85 M | Israel |
 |
Repare Therapeutics
RPTX
|
-84.7 M | - | - | $ 112 M |  Canada |
 |
uniQure N.V.
QURE
|
-199 M | $ 22.8 | 0.39 % | $ 1.31 B | Niderland |
 |
Rocket Pharmaceuticals
RCKT
|
-223 M | $ 2.61 | 1.95 % | $ 290 M | USA |
 |
Arcus Biosciences
RCUS
|
-353 M | $ 24.74 | 1.23 % | $ 2.66 B | USA |
 |
Regeneron Pharmaceuticals
REGN
|
4.5 B | $ 726.47 | 0.05 % | $ 76 B | USA |
 |
Replimune Group
REPL
|
-314 M | $ 13.15 | 0.61 % | $ 1.22 B | USA |
 |
Rafael Holdings
RFL
|
-290 K | $ 1.47 | 0.65 % | $ 43.3 M | USA |
 |
REGENXBIO
RGNX
|
-194 M | $ 7.76 | 4.44 % | $ 400 M | USA |
 |
Rigel Pharmaceuticals
RIGL
|
367 M | $ 47.79 | 1.36 % | $ 860 M | USA |
 |
Relay Therapeutics
RLAY
|
-276 M | $ 19.39 | 2.27 % | $ 3.33 B | USA |
 |
Avidity Biosciences
RNA
|
-685 M | $ 7.97 | 1.66 % | $ 1.1 B | USA |
 |
Royalty Pharma plc
RPRX
|
771 M | $ 56.66 | 0.36 % | $ 24.4 B | USA |
 |
Revolution Medicines
RVMD
|
-1.13 B | $ 207.68 | 0.5 % | $ 39.5 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
-197 K | $ 92.45 | 0.24 % | $ 6.01 B | USA |
|
Rezolute
RZLT
|
-77.6 M | $ 4.33 | 7.98 % | $ 450 M | USA |
 |
Sana Biotechnology
SANA
|
-244 M | $ 2.88 | 1.21 % | $ 729 M | USA |
 |
Seer
SEER
|
-73.6 M | $ 2.33 | 3.56 % | $ 129 M | USA |
 |
SIGA Technologies
SIGA
|
23.3 M | $ 3.48 | 2.96 % | $ 249 M | USA |
 |
Sol-Gel Technologies Ltd.
SLGL
|
-6.13 M | $ 78.95 | 9.65 % | $ 220 M | Israel |
|
Silence Therapeutics plc
SLN
|
-43.3 M | $ 10.14 | 0.78 % | $ 1.44 B |  Britain |
 |
SELLAS Life Sciences Group
SLS
|
-26.9 M | $ 11.63 | 3.62 % | $ 1.27 B | USA |
 |
Summit Therapeutics
SMMT
|
-1.08 B | $ 17.27 | 3.07 % | $ 12.9 B | Britain |
 |
Syndax Pharmaceuticals
SNDX
|
-285 M | $ 17.83 | 1.31 % | $ 1.54 B | USA |
 |
Soligenix
SNGX
|
-11.1 M | $ 0.36 | 0.6 % | $ 1.87 M | USA |
 |
Sanofi
SNY
|
7.85 B | $ 39.51 | 1.19 % | $ 48.2 B |  France |
 |
Spruce Biosciences
SPRB
|
-39 M | $ 45.42 | 2.1 % | $ 34.8 M | USA |